Videos
Standard Platinum-Based Chemo Following PARPi Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer
10/23/2025
Jennifer Scalici, MD, Winship Cancer Institute of Emory University, Atlanta, Georgia, explores the evolving role of platinum therapy following PARP inhibitor (PARPi) progression in the platinum-sensitive setting.
At the Great Debates in Solid Tumors Meeting in Miami, Florida, Dr Scalici argued that despite emerging data suggesting potential platinum-resistance post-PARPi, platinum remains standard of care, with patient selection and treatment timing key to optimizing outcomes.
